IntelliPharmaCeutics International (IntelliPharmaCeutics International) Total Inventories : $0.00 Mil (As of Aug. 2023)

View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Total Inventories?

IntelliPharmaCeutics International's total inventories for the quarter that ended in Aug. 2023 was $0.00 Mil. IntelliPharmaCeutics International's average total inventories from the quarter that ended in May. 2023 to the quarter that ended in Aug. 2023 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. IntelliPharmaCeutics International's Net-Net Working Capital per share for the quarter that ended in Aug. 2023 was $-0.42.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. IntelliPharmaCeutics International's Days Inventory for the three months ended in Aug. 2023 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. IntelliPharmaCeutics International's Inventory-to-Revenue for the quarter that ended in Aug. 2023 was 0.00.

IntelliPharmaCeutics International Total Inventories Historical Data

The historical data trend for IntelliPharmaCeutics International's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Total Inventories Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Total Inventories

Get a 7-Day Free Trial

0.25

0.35

0.11

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

IntelliPharmaCeutics International Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

IntelliPharmaCeutics International (OTCPK:IPCIF) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

IntelliPharmaCeutics International's Net-Net Working Capital Per Share for the quarter that ended in Aug. 2023 is

	Net-Net Working Capital Per Share (Q: Aug. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.4	+	0.75 * 0	+	0.5 * 0	-	14.442
-	0	-	0)	/	33.0927
=	-0.42

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

IntelliPharmaCeutics International's Days Inventory for the three months ended in Aug. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Aug. 2023 )	/	Cost of Goods Sold (Q: Aug. 2023 )	*	Days in Period
	=	0	/	0.018	*	365 / 4
	=	0.00

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

IntelliPharmaCeutics International's Inventory Turnover for the quarter that ended in Aug. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Aug. 2023 )	/	Average Total Inventories (Q: Aug. 2023 )
	=	0.018	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

IntelliPharmaCeutics International's Inventory to Revenue for the quarter that ended in Aug. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Aug. 2023 )	/	Revenue (Q: Aug. 2023 )
	=	0	/	0.069
	=	0.00

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

IntelliPharmaCeutics International Total Inventories Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

I4AA:Germany IPCI:Canada

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.